CR20200495A - NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) - Google Patents
NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174)Info
- Publication number
- CR20200495A CR20200495A CR20200495A CR20200495A CR20200495A CR 20200495 A CR20200495 A CR 20200495A CR 20200495 A CR20200495 A CR 20200495A CR 20200495 A CR20200495 A CR 20200495A CR 20200495 A CR20200495 A CR 20200495A
- Authority
- CR
- Costa Rica
- Prior art keywords
- peptides
- combination
- present
- tumor
- scaffolds
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 230000001024 immunotherapeutic effect Effects 0.000 title abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
<p>La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular <em>ex vivo </em>linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562211276P | 2015-08-28 | 2015-08-28 | |
GBGB1515321.6A GB201515321D0 (en) | 2015-08-28 | 2015-08-28 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
PCT/EP2016/070146 WO2017036936A1 (en) | 2015-08-28 | 2016-08-26 | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20200495A true CR20200495A (es) | 2020-11-24 |
Family
ID=54326487
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200492A CR20200492A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) |
CR20200494A CR20200494A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) |
CR20180174A CR20180174A (es) | 2015-08-28 | 2016-08-26 | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer |
CR20200495A CR20200495A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) |
CR20180423A CR20180423A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-0174) |
CR20200493A CR20200493A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20200492A CR20200492A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) |
CR20200494A CR20200494A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) |
CR20180174A CR20180174A (es) | 2015-08-28 | 2016-08-26 | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20180423A CR20180423A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-0174) |
CR20200493A CR20200493A (es) | 2015-08-28 | 2016-08-26 | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) |
Country Status (18)
Country | Link |
---|---|
US (7) | US10576132B2 (es) |
EP (2) | EP3341014A1 (es) |
JP (2) | JP6970974B2 (es) |
KR (3) | KR102515909B1 (es) |
CN (1) | CN107921111B (es) |
AU (3) | AU2016313684B2 (es) |
BR (1) | BR112018003460A2 (es) |
CA (2) | CA2996963A1 (es) |
CR (6) | CR20200492A (es) |
EA (2) | EA201890560A1 (es) |
GB (1) | GB201515321D0 (es) |
MA (7) | MA43460A1 (es) |
MX (1) | MX2018002480A (es) |
PE (2) | PE20181517A1 (es) |
SG (3) | SG10202001830PA (es) |
TW (15) | TWI722658B (es) |
UA (1) | UA124577C2 (es) |
WO (1) | WO2017036936A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201507030D0 (en) * | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
CN108250286B (zh) * | 2016-12-28 | 2021-06-08 | 香雪生命科学技术(广东)有限公司 | 源自于pasd1的肿瘤抗原短肽 |
WO2018189152A2 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
SG11201909058WA (en) | 2017-04-10 | 2019-10-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
AU2018298884A1 (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
PT3688155T (pt) * | 2017-09-28 | 2023-04-11 | Gavish Galilee Bio Appl Ltd | Uma plataforma universal para preparar um recetor de antígeno quimérico inibidor (icar) |
CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
CN109467596B (zh) * | 2018-11-12 | 2021-11-09 | 湖北省农业科学院畜牧兽医研究所 | 转录因子sp1在调控猪rtl1基因表达中的应用 |
CN109738929B (zh) * | 2018-12-03 | 2022-10-21 | 中国辐射防护研究院 | 一种基于居民食物最大消费量的剂量估算方法及*** |
TW202042836A (zh) * | 2019-02-18 | 2020-12-01 | 日商肽夢想股份有限公司 | 血球凝集素結合肽 |
EP3970739A1 (en) * | 2019-05-13 | 2022-03-23 | Itoh, Kyogo | Method for determining eligibility of cancer patients for peptide vaccine therapy |
CN110123453B (zh) * | 2019-05-31 | 2021-07-23 | 东北大学 | 一种基于无标记增强现实的手术导航*** |
CN111910000B (zh) * | 2020-07-02 | 2022-07-01 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及*** |
CA3217185A1 (en) * | 2021-04-19 | 2022-10-27 | Board Of Regents, The University Of Texas Systems | Methods and compositions comprising mhc class i peptides |
CN115607573B (zh) * | 2022-12-16 | 2023-05-23 | 北京大学第三医院(北京大学第三临床医学院) | 一种用于调节杀伤性t细胞活性的方法、药物及其应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11507501A (ja) * | 1995-06-05 | 1999-07-06 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | ヒトgタンパク質レセプターhgber32 |
EP1064022A4 (en) * | 1998-03-13 | 2004-09-29 | Epimmune Inc | HLA BINDING PEPTIDES AND THEIR APPLICATIONS |
US7342108B2 (en) * | 1998-06-25 | 2008-03-11 | The General Hospital Corporation | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof |
JP4315301B2 (ja) | 1998-10-30 | 2009-08-19 | 独立行政法人科学技術振興機構 | ヒトH37タンパク質と、このタンパク質をコードする cDNA |
US6680197B2 (en) * | 1998-12-28 | 2004-01-20 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
CA2311201A1 (en) * | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
US20040002068A1 (en) * | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
GB0119473D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
WO2003016523A1 (en) * | 2001-08-21 | 2003-02-27 | Millennium Pharmaceuticals, Inc. | Screen for cdc7 inhibitors |
US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
DE10316701A1 (de) | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
BRPI0410343A (pt) * | 2003-05-05 | 2006-05-30 | Pharmacia Italia Spa | formas truncadas de dbf4 humana, complexos com seus pares de interação e métodos para identificação de seus inibidores |
EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
US8536313B2 (en) * | 2007-07-10 | 2013-09-17 | Shionogi & Co., Ltd. | Monoclonal antibody having neutralizing activity against MMP13 |
SI2660248T1 (sl) * | 2007-07-27 | 2015-10-30 | Immatics Biotechnologies Gmbh | Nova imunoterapija proti možganskim tumorjem |
EP2562182B1 (en) | 2007-07-27 | 2015-10-07 | Immatics Biotechnologies GmbH | Novel immunogenic epitopes for immunotherapy |
AU2008311869B2 (en) * | 2007-10-17 | 2013-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for crystallizing G protein-coupled receptors |
CN102165688A (zh) | 2008-03-31 | 2011-08-24 | 新加坡科技研究局 | 高效率线性发射器 |
TW201000115A (en) * | 2008-06-11 | 2010-01-01 | Oncotherapy Science Inc | IQGAP3 epitope peptides and vaccines containing the same |
RS53782B1 (en) | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS |
EP2337795A2 (en) * | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
ITBO20090075A1 (it) * | 2009-02-13 | 2010-08-14 | Magneti Marelli Spa | Macchina elettrica con singolo statore e due rotori tra loro indipendenti e veicolo stradale provvisto di tale macchina elettrica |
GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
WO2012048291A2 (en) * | 2010-10-08 | 2012-04-12 | Proteapex Therapeutics Llc | Compositions and methods for inhibition of mmp:mmp-substrate interactions |
US9540433B2 (en) * | 2011-02-01 | 2017-01-10 | Genmab A/S | Human antibodies and antibody-drug conjugates against CD74 |
CN104081202A (zh) | 2011-09-12 | 2014-10-01 | 克里蒂科斯有限责任公司 | 检测靶分子的非侵入性方法 |
EP2788012A4 (en) | 2011-11-11 | 2015-08-05 | Cedars Sinai Medical Center | COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES |
US10501512B2 (en) * | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9500651B2 (en) * | 2012-08-15 | 2016-11-22 | Université de Montréal | Method for identifying novel minor histocompatibility antigens |
ES2925307T3 (es) * | 2012-09-14 | 2022-10-14 | Us Health | Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II |
US9134326B2 (en) | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
TWI777195B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(三) |
WO2015092710A1 (en) * | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
US20190346442A1 (en) | 2016-04-18 | 2019-11-14 | The Broad Institute, Inc. | Improved hla epitope prediction |
TW202016131A (zh) * | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
-
2015
- 2015-08-28 GB GBGB1515321.6A patent/GB201515321D0/en not_active Ceased
-
2016
- 2016-08-26 KR KR1020217031080A patent/KR102515909B1/ko active IP Right Grant
- 2016-08-26 MX MX2018002480A patent/MX2018002480A/es unknown
- 2016-08-26 UA UAA201808797A patent/UA124577C2/uk unknown
- 2016-08-26 TW TW108141492A patent/TWI722658B/zh active
- 2016-08-26 MA MA43460A patent/MA43460A1/fr unknown
- 2016-08-26 CR CR20200492A patent/CR20200492A/es unknown
- 2016-08-26 MA MA045073A patent/MA45073A/fr unknown
- 2016-08-26 PE PE2018001375A patent/PE20181517A1/es unknown
- 2016-08-26 TW TW108141499A patent/TWI722664B/zh active
- 2016-08-26 EP EP16762752.0A patent/EP3341014A1/en active Pending
- 2016-08-26 CR CR20200494A patent/CR20200494A/es unknown
- 2016-08-26 SG SG10202001830PA patent/SG10202001830PA/en unknown
- 2016-08-26 KR KR1020187007555A patent/KR20180038550A/ko not_active Application Discontinuation
- 2016-08-26 TW TW108141494A patent/TWI722659B/zh active
- 2016-08-26 TW TW108141491A patent/TWI722657B/zh active
- 2016-08-26 WO PCT/EP2016/070146 patent/WO2017036936A1/en active Application Filing
- 2016-08-26 MA MA43461A patent/MA43461B1/fr unknown
- 2016-08-26 PE PE2018000318A patent/PE20181164A1/es unknown
- 2016-08-26 TW TW108141497A patent/TWI722662B/zh active
- 2016-08-26 EA EA201890560A patent/EA201890560A1/ru unknown
- 2016-08-26 MA MA43458A patent/MA43458A1/fr unknown
- 2016-08-26 KR KR1020187023153A patent/KR102308798B1/ko active IP Right Grant
- 2016-08-26 TW TW109122012A patent/TWI782290B/zh active
- 2016-08-26 SG SG10202001831SA patent/SG10202001831SA/en unknown
- 2016-08-26 BR BR112018003460-6A patent/BR112018003460A2/pt active Search and Examination
- 2016-08-26 JP JP2018511114A patent/JP6970974B2/ja active Active
- 2016-08-26 MA MA43457A patent/MA43457A1/fr unknown
- 2016-08-26 TW TW108141488A patent/TWI722654B/zh active
- 2016-08-26 TW TW108141487A patent/TWI722653B/zh active
- 2016-08-26 MA MA042694A patent/MA42694A/fr unknown
- 2016-08-26 EP EP18201208.8A patent/EP3461494A1/en active Pending
- 2016-08-26 CR CR20180174A patent/CR20180174A/es unknown
- 2016-08-26 CR CR20200495A patent/CR20200495A/es unknown
- 2016-08-26 TW TW107128393A patent/TWI699377B/zh active
- 2016-08-26 TW TW105127400A patent/TW201708246A/zh unknown
- 2016-08-26 TW TW108141490A patent/TWI722656B/zh active
- 2016-08-26 TW TW108141489A patent/TWI722655B/zh active
- 2016-08-26 CR CR20180423A patent/CR20180423A/es unknown
- 2016-08-26 TW TW108141495A patent/TWI722660B/zh active
- 2016-08-26 CA CA2996963A patent/CA2996963A1/en active Pending
- 2016-08-26 MA MA43459A patent/MA43459A1/fr unknown
- 2016-08-26 TW TW108141496A patent/TWI722661B/zh active
- 2016-08-26 AU AU2016313684A patent/AU2016313684B2/en active Active
- 2016-08-26 CA CA3072922A patent/CA3072922A1/en active Pending
- 2016-08-26 EA EA201891874A patent/EA201891874A3/ru unknown
- 2016-08-26 CR CR20200493A patent/CR20200493A/es unknown
- 2016-08-26 CN CN201680050119.7A patent/CN107921111B/zh active Active
- 2016-08-26 SG SG10201807588TA patent/SG10201807588TA/en unknown
- 2016-08-26 TW TW108141498A patent/TWI722663B/zh active
-
2018
- 2018-05-17 US US15/982,293 patent/US10576132B2/en active Active
- 2018-05-17 US US15/982,500 patent/US10525114B2/en active Active
- 2018-10-18 AU AU2018250464A patent/AU2018250464B2/en active Active
-
2019
- 2019-11-04 US US16/673,619 patent/US10695411B2/en active Active
- 2019-11-04 US US16/673,608 patent/US10568950B1/en active Active
-
2020
- 2020-03-16 AU AU2020201896A patent/AU2020201896B2/en active Active
- 2020-05-29 US US16/887,765 patent/US10898557B2/en active Active
- 2020-06-29 US US16/915,420 patent/US10898558B2/en active Active
- 2020-09-10 US US17/017,358 patent/US11065316B2/en active Active
-
2021
- 2021-04-23 JP JP2021072989A patent/JP7506026B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500551A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
PH12018500848A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
CR20200494A (es) | NUEVOS PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y SOPORTES PARA EL USO EN EL TRATAMIENTO INMUNOTERAPÉUTICO DE VARIOS TIPOS DE CÁNCER (Divisional 2018-174) | |
CR20200555A (es) | PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE MAMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0135) | |
CR20200471A (es) | PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522) | |
CR20200432A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 2. 2018-74) | |
CR20210233A (es) | NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) | |
PH12017502279A1 (en) | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers | |
CR20230562A (es) | NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-000579) | |
MX2022001319A (es) | Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer. | |
MX2018010875A (es) | Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores. | |
MY196837A (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
MX2022005570A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer. |